Paysign's 2025 Performance: A Year of Exceptional Growth and Inflection Point

Paysign, a leading player in the patient affordability space, has just reported its fourth quarter and full year financial results for 2025, showcasing continued strength and exceptional growth across all key metrics. The company's President and CEO, Mark Newcomer, highlighted these achievements during the recent earnings call.

For the full year, revenue increased by a staggering 40.5% to $82 million, with net income rising 98% to $7.6 million. Adjusted EBITDA also saw significant growth, increasing by 107% to $19.9 million. Perhaps most notably, operating margins expanded by an impressive 723 basis points, signaling that the company has reached a crucial inflection point where future revenue growth should drive increasing operating leverage and profitability.

The patient affordability business continued to thrive, with annual revenue growing 168% year-over-year to $33.9 million compared to $12.7 million in 2024. The number of claims processed increased by approximately 79%, further underscoring the platform's success. PaySign's patient affordability platform helps pharmaceutical companies ensure patients can access high-cost medications by administering co-pay assistance programs.

In 2025, the company's dynamic business rules technology helped deliver nearly $1 billion in financial assistance to patients, supporting access to high-cost therapies for more than 840,000 individuals. This solution saved PaySign's clients over $325 million last year alone and has already saved them almost $150 million this year. The platform's scalability was further demonstrated by the successful onboarding of new programs from existing clients, with four additional programs added from one of the nation's largest pharmaceutical manufacturers.

Paysign now boasts active programs with six of the top 10 U.S. pharmaceutical manufacturers ranked by revenue, and the company is well-positioned to capitalize on future growth opportunities. Next month, PaySign will attend the Asembia Specialty Pharmacy Summit in Las Vegas, where it expects strong interest from potential clients evaluating its solutions.

Mark Newcomer emphasized that PaySign's continued success is driven by the durability of demand and the scalability of its platform. As the company looks to the future, investors can be confident in PaySign's ability to deliver exceptional growth and profitability.